IGM Biosciences Inc Clinical Update Conference Call Transcript
Good day, and thank you for standing by. Welcome to the IGM-8444 Clinical Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I'd now like to hand the conference over to Fred Schwarzer, CEO of IGM Biosciences. Please go ahead.
Thank you, operator, and I would like to thank all of you for joining us during your very busy ASCO schedule. On behalf of IGM, I'm joined today by Dr. Chris Takimoto, Chief Medical Officer; and Dr. Eric Humke, Vice President of Clinical Development. Eric leads our IGM-8444 clinical development program. It is also our great honor and pleasure to have Dr. Susanna Ulahannan of the Oklahoma University Health Stephenson Cancer Center with us on the call this evening.
I will start with a few introductory remarks, and then I will turn the call over to Chris to provide some historical and scientific background on oncology therapeutic efforts directed at the Death Receptor 5 target. Chris will then
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |